Research programme: influenza A virus H7N9 combination vaccine - Replikins

Drug Profile

Research programme: influenza A virus H7N9 combination vaccine - Replikins

Alternative Names: Synthetic H7N9 pandemic influenza combination vaccine - Replikins

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Replikins
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Influenza-A-virus-infections(Prevention) in USA
  • 23 Apr 2013 Early research in Influenza A virus infections in USA (unspecified route)
  • 18 Apr 2013 Influenza A virus H7N9 combination vaccine - Replikins is available for licensing as of 18 Apr 2013. www.replikins.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top